Ken Griffin Harvard Bioscience Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.64 - $3.54 $1,320 - $1,770	-500 Reduced 41.67%	700 $1,000
Q2 2024 Aug 14, 2024	SELL	$2.77 - $4.63 $7,756 - $12,964	-2,800 Reduced 70.0%	1,200 $3,000
Q1 2024 May 15, 2024	BUY	$4.02 - $5.39 $16,079 - $21,560	4,000 New	4,000 $16,000
Q3 2023 Nov 14, 2023	SELL	$4.0 - $5.82 $12,800 - $18,624	-3,200 Reduced 24.24%	10,000 $43,000
Q2 2023 Aug 14, 2023	BUY	$4.19 - $6.16 $47,766 - $70,224	11,400 Added 633.33%	13,200 $72,000
Q1 2023 May 15, 2023	BUY	$2.45 - $4.22 $4,165 - $7,174	1,700 Added 1700.0%	1,800 $7,000
Q4 2022 Feb 14, 2023	BUY	$2.12 - $2.86 $212 - $286	100 New	100 $0

30.6M

700

2.1K

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $89.1M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.